Johan F. K. F. Ilvemark

Johan F. K. F. Ilvemark

Auto-generated profile, based on publicly available information

Johan F. K. F. Ilvemark

Department of Gastroenterology, Herlev and Gentofte, Copenhagen University Hospital, 2730 Herlev, Denmark

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
JIJohan F K F Ilvemark
Johan F K F Ilvemark
THTawnya Hansen
Tawnya Hansen
TGThomas M Goodsall
Thomas M Goodsall
JSJakob B Seidelin
Jakob B Seidelin
HFHeba Al- Farhan
Heba Al- Farhan
Rune WilkensRune Wilkens
Rune Wilkens
No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting. Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound [IUS] assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts [n = 18] rated an initial 196 statements [RAND/UCLA process, scale 1–9]. Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively. Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included; 83% [40/48] of included studies showed a low concern of applicability, and 96% [46/48] had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease. Response criteria and time points of response assessment varied between studies, complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response, to incorporate into future prospective studies.

13 June 2022 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
JIJohan F K F Ilvemark
Johan F K F Ilvemark
Rune WilkensRune Wilkens
Rune Wilkens
PTPeter Thielsen
Peter Thielsen
ADAnders Dige
Anders Dige
TBTrine Boysen
Trine Boysen
JSJakob Benedict Seidelin
Jakob Benedict Seidelin
Our aim was to determine if transabdominal intestinal ultrasound changes after 48 ± 24 h of intravenous corticosteroids can predict treatment outcomes in hospitalised patients with severe ulcerative colitis. We performed a blinded observational multicentre study. Ultrasound parameters were assessed before treatment initiation, after 48 ± 24 h, and 6 ± 1 days. Treatment response was determined within 7 days by two outcome measures: 1] partial Mayo score reduction; 2] no administration of rescue therapy. Out of 69 recruited patients, 56 were included in the final analysis, with 37 responders. The colon segment with the highest baseline bowel wall thickness was analysed, being the sigmoid in all patients. There was no difference in baseline bowel wall thickness between responders and non-responders in the partial Mayo score outcome. At 48 ± 24 h, a significant difference between responders and non-responders was identified in both absolute bowel wall thickness [median 3.1 mm vs 4.9 mm; p <0.0001], absolute reduction [-1.9 mm vs -0.2 mm; p <0.001], and relative reduction [-35.9% vs -4.1%; p 20% reduction had the highest odds ratio (22.6 [4.2, 201.2]; p = 0.001) for determining response. Similar results were seen for the rescue therapy outcome. Changes in bowel wall thickness, after 48 ± 24 h following intravenous corticosteroid treatment in hospitalised patients with severe ulcerative colitis, identify responders with high accuracy and might be used as an early marker to guide accelerated rescue therapy.

28 June 2024 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
JIJohan F K F Ilvemark
Johan F K F Ilvemark
Rune WilkensRune Wilkens
Rune Wilkens
PTPeter Thielsen
Peter Thielsen
ADAnders Dige
Anders Dige
TBTrine Boysen
Trine Boysen
JSJakob B Seidelin
Jakob B Seidelin
Background and Aims: Reliable and easily accessible objective markers of disease activity to predict long-term treatment outcomes in severe ulcerative colitis [UC] are missing. We aimed to investigate if intestinal ultrasound [IUS] might predict long-term outcomes in hospitalised patients with severe UC, treated with intravenous [IV] corticosteroids. Methods: Hospitalised patients with severe UC and IUS inflammation (bowel wall thickness [BWT] > 3.0 mm) starting IV corticosteroids were recruited at three university hospitals in Denmark. IUS was performed before treatment and 48 ± 24 h, 6 ± 1 days, and 3 months after treatment initiation. Time until colectomy or need for new interventions was registered together with Mayo score at 3 months and partial Mayo score [pMayo] at 12 months. Follow-up time was 12 months. Results: In the final analysis, 56 patients were included; 45 [80%] patients needed intervention, including nine colectomies, during the 12-month follow-up. After 48 ± 24 h, no patient with a BWT < 3 mm needed a colectomy, p = 0.04. BWT ≥ 4 mm showed an increased risk of colectomy {odds ratio 9.5 (95% confidence interval [CI] 1.5–186), p = 0.03}, whereas a BWT ≥ 3 mm showed an increased risk of intervention (3.6 [1.1–12.5], p = 0.03). A BWT ≥ 4 mm resulted in a significantly shorter time until both colectomy, p = 0.03, and treatment intensification (mean days 75 [95% CI 24–127] vs 176 [119–233], p = 0.005). However, neither IUS parameters nor pMayo score, C-reactive protein [CRP], haemoglobin, or p-albumin could predict remission at 3 and 12 months. Conclusion: BWT, assessed at 48 h post intravenous corticosteroid initiation in patients hospitalised with severe UC, may identify patients with an increased risk of short- and long-term colectomy and predict a more aggressive short-term disease course.

1 March 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
GMGorm Roager Madsen
Gorm Roager Madsen
Rune WilkensRune Wilkens
Rune Wilkens
MAMohamed Attauabi
Mohamed Attauabi
JIJohan F K F Ilvemark
Johan F K F Ilvemark
KTKlaus Theede
Klaus Theede
JBJohan Burisch
Johan Burisch
Background and Aims: This study assesses the prognostic role of intestinal ultrasound (IUS) in determining the disease course of ulcerative colitis (UC) in the first year after diagnosis. Methods: A prospective, multicenter population-based inception cohort study was conducted on patients newly diagnosed with UC. Patients with left-sided or extensive UC underwent IUS assessments at diagnosis, 3 months, and 12 months, alongside symptomatic, biochemical, and endoscopic evaluations. Transmural remission was defined as bowel wall thickness ≤3 mm without color Doppler signal in all segments. Results: From May 2021 to April 2023, 193 patients with left-sided or extensive UC were included. Inflammatory findings on IUS at diagnosis were associated with symptomatic, biochemical, and endoscopic markers of inflammation, but not with diagnostic delay. IUS-detected inflammation at diagnosis was an independent predictor for colectomy within the first 3 months, with bowel wall thickness >6 mm as the optimal cutoff (odds ratio 38, 95% confidence interval, 8–270, P < .0001). Three months after diagnosis, 59% of patients achieved transmural remission, which was associated with higher rates of steroid-free clinical remission in all subsequent follow-ups, as well as a reduced need for steroids during follow-up (6% vs. 19%, P = .036). Furthermore, transmural remission at 3 months increased the likelihood of steroid-free clinical remission, as well as transmural and complete remission, at 12 months. Conclusions: Findings by IUS at the time of diagnosis predict early colectomy risk in UC. Our results underscore that transmural remission is a feasible treatment target in early UC, and significantly impacts the disease course.

30 September 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ADAlix Démaris
Alix Démaris
EWElla S. K. Widigson
Ella S. K. Widigson
JIJohan F. K. F. Ilvemark
Johan F. K. F. Ilvemark
CSCasper Steenholdt
Casper Steenholdt
JSJakob B. Seidelin
Jakob B. Seidelin
CKCharlotte Kloft
Charlotte Kloft
Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis α monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modelling of IFX PK in this population remain. This is even more true for acute severe UC (ASUC) patients for which early prediction of IFX pharmacokinetic (PK) could highly improve treatment outcome. Thus, this review aims to compile and analyse published population PK models of IFX in UC and ASUC patients, and to assess the current knowledge on disease activity impact on IFX PK. For this, a semi-systematic literature search was conducted, from which 26 publications including a population PK model analysis of UC patients receiving IFX therapy were selected. Amongst those, only four developed a model specifically for UC patients, and only three populations included severe UC patients. Investigations of disease activity impact on PK were reported in only 4 of the 14 models selected. In addition, the lack of reported model codes and assessment of predictive performance make the use of published models in a clinical setting challenging. Thus, more comprehensive investigation of PK in UC and ASUC is needed as well as more adequate reports on developed models and their evaluation in order to apply them in a clinical setting.

6 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KCKatrine Risager Risager Christensen
Katrine Risager Risager Christensen
OAOsamah Saadi Al-Obaidi
Osamah Saadi Al-Obaidi
SBSine Buhl
Sine Buhl
JIJohan F. Ilvemark
Johan F. Ilvemark
CSCasper Steenholdt
Casper Steenholdt
Mark Andrew AinsworthMark Andrew Ainsworth
Mark Andrew Ainsworth
Background/Objectives: The combined goal of achieving both clinical and endoscopic remission has highlighted the need for strategies that support a treat-to-target approach in inflammatory bowel disease (IBD). A proactive monitoring strategy involves scheduled assessments regardless of symptoms to detect subclinical disease activity and enable timely treatment adjustments, whereas a reactive approach initiates evaluation only in response to clinical deterioration or objective signs of active disease. This study investigated whether proactive monitoring improves the achievement of treatment goals compared with a reactive strategy. Methods: In this prospective cohort study carried out between September 2020 and July 2022, patients with IBD receiving biologic therapy were managed according to a predefined proactive monitoring schedule and prospectively followed for one year. A control group, matched for age, sex, diagnosis, and treatment, was enrolled from another tertiary IBD center using a reactive monitoring strategy; their clinical course over one year was reconstructed retrospectively from medical records. All patients underwent colonoscopy assessment at one year. The primary outcome was treatment failure, defined as inadequate mucosal healing or symptom control, the need for intestinal surgery, or discontinuation of biologic therapy due to insufficient efficacy. Results: A total of 162 patients were included (91 managed proactively and 71 managed reactively). In the intention-to-treat population, treatment failure occurred in 67 patients (74%, 95% confidence interval (CI) 63–84%) in the intervention group and 60 patients (85%, 95% CI 75% to 94%) in the control group (difference 11%, CI −3% to 25%, p = 0.13). In the per-protocol analysis, 44 of 69 patients (64%, CI 50% to 78%) in the intervention group experienced treatment failure compared with 43 of 53 patients (81%, CI 60% to 93%) in the control group (difference 17%, CI −1% to 36%, p = 0.06). Patients in the proactive monitoring group underwent significantly more disease-monitoring assessments than those managed reactively. Conclusions: Proactive monitoring numerically improved combined clinical and endoscopic outcomes compared with reactive management, but this did not reach statistical significance and resulted in substantially greater healthcare resource utilization.